George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
They have a big following on LinkedIn and are based around the world.
https://www.linkedin.com/feed/update/urn:li:activity:6948154504450101248?updateEntityUrn=urn%3Ali%3Afs_feedUpdate%3A%28V2%2Curn%3Ali%3Aactivity%3A6948154504450101248%29
https://fortune.com/2022/06/29/monkeypox-emergency-committee-reconvened-by-who-due-to-evolving-situation/
Obviously a fast evolving situation and one that nobody seems to have got to grips with because of covid complacency. Right place, right time (again) for Novacyt?
https://www.who.int/news-room/speeches/item/who-director-general-s-statement-on-the-report-of-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee--regarding-the-multi-country-monkeypox-outbreak
What makes the current outbreak especially concerning is the rapid, continuing spread into new countries and regions and the risk of further, sustained transmission into vulnerable populations including people that are immunocompromised, pregnant women and children.
That is why it is urgent that all Member States, communities and individuals take the recommendations of the Committee for stepped-up surveillance, improved diagnostics, community engagement and risk communication.
In short, another potentially strong revenue stream for Novacyt (as long as they finally release the assay).
Pebbles, you'll be surprised how the prospect of having to give evidence at court and face a huge costs bill sharpens the mind. The chances of settlement increase as the dispute goes on. C 12-18 months from here if it goes the full hog.
Hi sorry to disappoint but £30m will not be included afterwards or as part 36. The company have obviously decided that this element of the claim is not as watertight as the rest of the counterclaim. So yes it stinks but in some ways I am pleased because it backs up their statements that they have strong grounds. I suspect we will have issued part 36 whilst filing the defence and counterclaim but they can't RNS this (the judge can't find out).
DRB,
1) good question. I thought the same. I can only assume they don't think it's a strong claim contractually and therefore best not to pursue especially when all along they have said how strong their claim is. Ultimately a good approach if it ever goes to court because the judge will see they are playing it straight (rather than add on a lump like DHSC did).
2) the court will not have set the timetable yet, that will happen in the next few weeks. Suffice to say the next step will almost definitely be a 'stay' (short halt) in proceedings where the parties try and settle.
I'm as desperate as the rest of you for substantive news but he's definitely stepping it up a gear. Something tells me that this is not AGM related but that he has got to grips with the company and is taking it where he wants it to go.
https://www.linkedin.com/posts/david-allmond-93254846_singapores-dengue-emergency-is-a-climate-activity-6940413202325237761-oxqk?utm_source=linkedin_share&utm_medium=android_app
Not quite an interview and nothing new I don't think but nice to see his face nevertheless. P.36
https://www.insidermedia.com/publications/south-east-business-insider
And another...https://www.telegraph.co.uk/global-health/science-and-disease/multi-pathogen-testing-future-diagnostics/
https://www.theguardian.com/commentisfree/2022/may/25/monkeypox-disease-climate-change
Obviously early days but if it does spread more, then testing and in particular PCR testing will be in the limelight again. See link from WHO in particular
"Detection of viral DNA by polymerase chain reaction (PCR) is the preferred laboratory test for monkeypox. The best diagnostic specimens are directly from the rash – skin, fluid or crusts, or biopsy where feasible. Antigen and antibody detection methods may not be useful as they do not distinguish between orthopoxviruses. "
https://www.who.int/health-topics/monkeypox#tab=tab_1
Another new senior appointment, with a view to grow further... current sp movements are like watching paint dry but once the paint is fully dry I'm hoping it will create a beautiful picture.
https://www.linkedin.com/posts/morrisonian_lifesciences-activity-6930913879002640384-iL42?utm_source=linkedin_share&utm_medium=android_app
As well as M&A activity adding to the £100m I also get the impression that the £100m is on the base level tests and that any further outbreaks which DA said will happen would add significantly to this figure (as it did with Covid). The key here is that any outbreak gives them more money, more connections, better reputation etc which in turn all enhances the base level tests and the core business so it is a continuous motion of growth (if executed successfully).
Thanks as always Hillseeker, your summary was spot on! Look forward to the £15 party, sure we are going to have to wait a lot longer than we all first hoped but it will make the drink in your pub taste even better.